Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse

Cancer

Volumn 112, Issue 9, 2008, Pages 1983-1991

  Hijiya, Nobuko ^a,b,c   Stewart, Clinton F ^a,b   Zhou, Yinmei ^a   Campana, Dario ^a,b   Coustan Smith, Elaine ^a   Rivera, Gaston K ^a   Relling, Mary V ^a,b   Pui, Ching Hon ^a,b   Gajjar, Amar ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Induction therapy; Pediatric; Relapse; Topotecan

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARAGINASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; IDARUBICIN; LACTONE DERIVATIVE; MERCAPTOPURINE; METHOTREXATE; TENIPOSIDE; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BLAST CELL; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CAUSE OF DEATH; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DEHYDRATION; DIAPER DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EDEMA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INCIDENCE; INFECTION; KIDNEY FAILURE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIVER TOXICITY; MALE; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; NEUROTOXICITY; PAIN; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; THROMBOSIS; TREATMENT RESPONSE; VIRUS INFECTION; WEIGHT GAIN; ADOLESCENT; INFANT; LYMPHATIC LEUKEMIA; MORTALITY; PRESCHOOL CHILD; RECURRENT DISEASE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; FEMALE; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; TOPOTECAN; VINCRISTINE;

EID: 42449146087     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23395     Document Type: Article

References (32)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
2. Chessells JM. Relapsed lymphoblastic leukaemia in children: a continuing challenge. Br J Haematol. 1998;102:423-438.
3. Henze G, von Stackelberg A. Treatment of relapsed acute lymphoblastic leukemia. In: Pui CH, ed. Treatment of Acute Leukemias - New Directions for Clinical Research, Vol 1. Totowa, NJ; Humana Press, Inc.; 2003:199-219.
4. Hijiya N, Gajjar A, Zhang Z, et al. Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse. Leukemia. 2004;18:1581-1586.
5. Rivera GK, Zhou Y, Hancock ML, et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer. 2005;103:368-376.
6. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993;85:271-291.
7. Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995;36:393-403.
8. Santana VM, Zamboni WC, Kirstein MN, et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res. 2003;9:633-640.
9. Furman WL, Stewart CF, Kirstein M, et al. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a Pediatric Oncology Group study. J Clin Oncol. 2002;20:1617-1624.
10. Stewart CF, Iacono LC, Chintagumpala M, et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol. 2004;22: 3357-3365.
11. Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol. 1996;14:1504-1511.
12. Gore SD, Rowinsky EK, Miller CB, et al. A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clin Cancer Res. 1998;4:2677-2689.
13. Kaufmann SH, Karp JE, Letendre L, et al. Phase I and pharmacologic study of infusional topotecan and carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res. 2005;11:6641-6649.
14. Mattern MR, Hofmann GA, Polsky RM, Funk LR, McCabe FL, Johnson RK. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res. 1993;5:467-474.
15. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2691-2696.
16. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351:550-554.
17. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol. 1994;12:1946-1954.
18. Zamboni WC, Gajjar AJ, Heideman RL, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res. 1998;4:783-789.
19. Zamboni WC, Bowman LC, Tan M, et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol. 1999;43:454-460.
20. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide, 1st ed. Los Angeles, Calif: Biomedical Simulations Resource; 1990.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1968;53:457-481.
22. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34:541-554.
23. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16: 1141-1154.
24. Rivera GK, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet. 1991;337:61-66.
25. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338:499-505.
26. Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
27. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004;104:2690-2696.
28. Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol. 2000;18:2459-2467.
29. Kolb EA, Steinherz PG. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia. 2003;17:1967-1972.
30. Gerrits CJ, Schellens JH, Burris H, et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res. 1999;5:69-75.
31. Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol. 2006;24:563-570.
32. Rodriguez-Galindo C, Radomski K, Stewart CF, Furman W, Santana VM, Houghton PJ. Clinical use of topoisomerase I inhibitors in anticancer treatment. Med Pediatr Oncol. 2000;35:385-402.